| Keywords: |
adult; clinical trial; doxorubicin; multimodality cancer therapy; united states; combined modality therapy; antineoplastic agent; dacarbazine; neoplasm recurrence, local; antineoplastic combined chemotherapy protocols; radiotherapy; cyclophosphamide; pathology; sarcoma; cancer center; tumor recurrence; soft tissue sarcoma; cancer care facilities; new york city; clinical trials; soft tissue neoplasms; soft tissue tumor; middle age; prognosis; human; male; female; article; support, non-u.s. gov't; support, u.s. gov't, p.h.s.
|
